🏛️ Verified NIH Record • Updated 2026-05-13
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer (NCT06970847)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Clarity Pharmaceuticals Ltd
🩺 Plain-English Summary (8th-Grade Level)
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Who can join: Review the eligibility criteria below.
Location: UC Irvine — Irvine, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- UC Irvine — Irvine, California
- Comprehensive Urology Medical Group — Los Angeles, California
- Alarcon Urology Center — Montebello, California
- Biogenix Molecular — Miami, Florida
- Endeavor Health- Glenbrook Hospital — Glenview, Illinois
- Indiana University Health-IU Simon Cancer Center — Indianapolis, Indiana
- XCancer Research Network / LCMC Health EJGH — Metairie, Louisiana
- M. Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
- St. Louis University — St Louis, Missouri
- XCancer — Omaha, Nebraska
- Albany Medical College — Albany, New York
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Urology Associates, P.C. — Nashville, Tennessee
- Urology Clinics of North Texas — Dallas, Texas
- The Urology Place — San Antonio, Texas
- Summit Urology — Murray, Utah
- Intermountain Medical Center — Salt Lake City, Utah
- St. Vincent's Hospital, Sydney — Darlinghurst, New South Wales
- Sydney Adventist Hospital — Wahroonga, New South Wales
- Westmead Private Hosptial — Westmead, New South Wales
- Royal Brisbane and Women's Hospital — Herston, Queensland
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.